Given that IDH2 also performs catalytic actions on isocitric acid, by dehydrogenating it to form α-ketoglutarate and NADPH, we speculate that cancer cells may themselves provide more NADPH and TCA cycle intermediates to maintain hypoxia survivability through G6PD and IDH2 pathways (Fig. 8e). This evidence concerns the gene IDH2 and cancer.